Compositions useful for treating parkinsonism
AssigneeSchering Corporation
InventorElijah H. Gold
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds of the formula: ##EQU1## wherein Ad is 1-adamantyl; R is H or CH.sub.3 ; X is COOM or CH.sub.2 ##EQU2## wherein M is H or a pharmaceutically acceptable cation, and R.sub.1 is lower n-alkyl; and the pharmaceutically acceptable salts thereof. Preferred are ethyl-4-[N-(1-adamantyl)-N-methylamino]butyrate, 3-[N-(1-adamantyl-N-methylamino)]propionic acid and their pharmaceutically acceptable salts. These compounds are particularly useful in the treatment of parkinsonism.
Claims5
A process for treating symptoms of parkinsonism, which comprised administering to a mammal suffering from parkinsonism a therapeutically effective quantity of an N-adamantylmethylamino derivative selected from the group consisting of 3-[N-(1-adamantylamino)]propionic acid and a lower n-alkyl ester of 4-[N-(1-adamantyl)-N-methylamino]butyric acid and a pharmaceutically acceptable salt thereof.
A pharmaceutical composition for the treatment of the symptoms of parkinsonism which comprises an amount effective to alleviate the symptoms of parkinsonism of an N-adamantylamino compound selected from the group consisting of 3-[N-(1-adamantylmethylamino)]propionic acid and the lower alkyl ester of 4-[N-(1-adamantyl)-N-methylamino]butyric acid and the pharmaceutically acceptable salts thereof together with a pharmaceutically acceptable carrier compatible with said compound.
Dependencies are inferred from the claim text.